Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice.
To understand the underlying pharmacological basis and the molecular mechanism of Taxol in therapy of cervical carcinoma (CC) disease, we need to explore the effect of Taxol on CC-related genes and pro-apoptosis and anti-apoptosis genes expression. Immunohistochemistry, western blot and reverse transcription-polymerase chain reaction were applied to examine postive expression levels of Bcl-2, Bax and Caspase-3, HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA expression in tumour of CC mice. Results showed that treatment of Taxol could increase the inhibition rate of tumour growth, positive expression levels of Caspase-3, Bax and decrease positive expression levels of Bcl-2 and Bcl-2/Bax, expression levels of HGF, MACC1 and C-met proteins and MACC1 mRNA in tumour tissue of CC mice. It can be concluded that inhibitory activity of Taxol against tumour growth in CC mice is closely associated with its modulating positive expression of Bcl-2, Bax, Caspase-3, expression of HGF, MACC1, Caspase-3 and C-met proteins and MACC1 mRNA in tumour of CC mice. In conclusion, HGF, MACC1 and C-met genes involve into malignant cervical tumors occurrence, development and prognosis, and might become potential molecular target therapy site of cervical cancer. Taxol intervention may serve as a multi-targeted CC therapeutic capable of inducing selective cancer cell death.
Department of Obstetrics and Gynecology, Yancheng City First People's Hospital, Yancheng, 215006, China.
Xiao-Ping
XP
Chen
Xin-Ping
XP
Ren
Jian-Yun
JY
Lan
You-Guo
YG
Chen
Zong-Ji
ZJ
Shen
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D017228:Hepatocyte Growth Factor / Q000096:biosynthesis*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000096:biosynthesis*; D051379:Mice; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D017239:Paclitaxel / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D019859:Proto-Oncogene Proteins c-met / Q000096:biosynthesis*; D015534:Trans-Activators; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
C553307:HGF protein, mouse; D047908:Intracellular Signaling Peptides and Proteins; C575027:MACC1 protein, mouse; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D015534:Trans-Activators; D017228:Hepatocyte Growth Factor; D019859:Proto-Oncogene Proteins c-met; D017239:Paclitaxel